Curated News
By: NewsRamp Editorial Staff
September 24, 2026
Creative Biolabs Expands Retrovirus Antibody Portfolio
TLDR
- Creative Biolabs' expanded retrovirus antibody portfolio gives researchers a competitive edge in HIV-1, HIV-2, and HTLV-1 studies.
- Creative Biolabs offers antibodies against HIV-1 gp140, HIV-2 gp36, and HTLV-1 gag p19 for viral protein research and assay development.
- Creative Biolabs' new antibodies support research on HIV and HTLV-1, potentially leading to better diagnostics and treatments for global health.
- Creative Biolabs has launched antibodies targeting key retroviral proteins, including HIV-1 gp140, HIV-2 gp36, and HTLV-1 gag p19.
Impact - Why it Matters
This expansion matters because human retroviruses like HIV-1, HIV-2, and HTLV-1 continue to pose significant global health challenges, and research into their structural and envelope proteins is essential for developing effective vaccines, diagnostics, and therapies. By providing well-characterized antibodies against key targets such as gp140, gp36, and gag p19, Creative Biolabs empowers scientists to better understand viral entry, immune evasion, and pathogenesis. These tools can accelerate the discovery of broadly neutralizing antibodies, improve assay development, and ultimately contribute to the fight against retroviral diseases that affect millions worldwide. As the scientific community strives for an HIV vaccine and better treatments for HTLV-1-associated diseases, access to reliable research reagents is a critical piece of the puzzle.
Summary
Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1, addressing a critical need in virology, immunology, vaccine development, and diagnostic assay development. The company’s retrovirus-focused reagents are designed to support studies of viral entry, epitope recognition, immune responses, and assay development, offering researchers new tools to dissect the biology of these clinically significant human retroviruses.
At the forefront of HIV-1 research is the viral envelope glycoprotein gp140, an uncleaved ectodomain that serves as a primary target for broadly neutralizing antibodies and vaccine design. Creative Biolabs now offers an anti-gp140 HIV-1 antibody for research applications involving HIV-1 envelope biology and antigen recognition. For HIV-2, which presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates, the company provides antibodies targeting gp36, a key envelope-associated antigen useful for studying antigen recognition, cross-reactivity, and HIV-2-focused assay concepts. Beyond HIV, Creative Biolabs addresses HTLV-1, the causative agent of adult T-cell leukemia/lymphoma and HTLV-1-associated myelopathy. Its anti-HTLV-1 gag p19 antibody is intended for research applications such as Western blot, ELISA, and immunohistochemistry, supporting investigations into HTLV-1 pathogenesis.
A senior scientist at Creative Biolabs emphasized that retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats. By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, the company aims to give researchers additional options for studying viral proteins, antigen recognition, and assay development. Creative Biolabs also provides custom antibody development services for virology and infectious disease research, with more information available at https://www.antibody-creativebiolabs.com/. All products are for research use only, not for diagnostic or therapeutic procedures.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, Creative Biolabs Expands Retrovirus Antibody Portfolio
